FES Antikörper
-
- Target Alle FES Antikörper anzeigen
- FES (Feline Sarcoma Oncogene (FES))
-
Reaktivität
- Maus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser FES Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Produktmerkmale
- Polyclonal Antibody
- Aufreinigung
- Affinity purification
- Immunogen
- Recombinant fusion protein of human FES (NP_001137256.1).
- Isotyp
- IgG
- Top Product
- Discover our top product FES Primärantikörper
-
-
- Applikationshinweise
- WB 1:500-1:2000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
- Target
- FES (Feline Sarcoma Oncogene (FES))
- Andere Bezeichnung
- FES (FES Produkte)
- Synonyme
- FPS antikoerper, RGD1564385 antikoerper, AI586313 antikoerper, BB137047 antikoerper, c-fes antikoerper, FES antikoerper, c-fps antikoerper, FES proto-oncogene, tyrosine kinase antikoerper, feline sarcoma oncogene antikoerper, FES antikoerper, Fes antikoerper, fes antikoerper
- Hintergrund
- This gene encodes the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. The gene product has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia but it is also involved in normal hematopoiesis as well as growth factor and cytokine receptor signaling. Alternative splicing results in multiple variants encoding different isoforms.
- Molekulargewicht
-
Observed_MW: 98 kDa
Calculated_MW: 78 kDa/85 kDa/86 kDa/93 kDa
- Gen-ID
- 2242
- UniProt
- P07332
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Signaling Events mediated by VEGFR1 and VEGFR2
-